MedTrace Logo

Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)

NCT02546154 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 359

Last updated 2019-05-23

No results posted yet for this study

Summary

The objective is to monitor and quality assure the efficacy, including effects on quality of life, and safety of Monofer® in Chronic Kidney Disease and Inflammatory Bowel Disease patient populations when Monofer® is used according to the Monofer® label (Summary of Product Characteristics, SPC) in current clinical practice and where standard routines are being followed.

Conditions

  • Iron Deficiency Anaemia

Interventions

DRUG

10% Iron Isomaltoside 1000

Standard clinical practice and following the Monofer® label (SPC)

Sponsors & Collaborators

  • BioStata

    collaborator INDUSTRY

  • Pharmacosmos UK Ltd

    lead INDUSTRY

Principal Investigators

  • Sylvia Simon, PhD · Pharmacosmos A/S

  • Jason Moore, BMedSci, BMBS, FRCP · Royal Devon and Exeter Hospital NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-22
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02546154 on ClinicalTrials.gov